Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
ANIK
#2995
Anika Therapeutics Inc
14.360
0
+14.42%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+14.42%
Aylık değişim
+55.50%
6 aylık değişim
+41.62%
Yıllık değişim
+41.62%
Önceki kapanış
12.550
0
Open
14.360
0
Bid
Ask
Low
14.360
0
High
14.360
0
Hacim
44
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
ANIK
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
14.33 M
14.47 M
14.63 M
14.85 M
14.18 M
—
Valuation ratios
Enterprise value
552.74 M
423.97 M
345.05 M
263.63 M
177.71 M
516.83 M
Price to earnings ratio
-26.78
127.96
-28.9
-4.02
-4.3
-14.88
Price to sales ratio
4.93
3.55
2.75
1.99
2.02
6.08
Price to cash flow ratio
49.27
62.44
97.36
185.74
44.85
137.02
Price to book ratio
2.36
1.83
1.5
1.56
1.57
2.37
Enterprise value to EBITDA ratio
-9.28
-41.24
-28.67
-3.36
-29.24
-41.01
Profitability ratios
Return on assets %
0.07
0.01
0.04
0.31
0.28
0.17
Return on equity %
0.09
0.01
0.05
0.39
0.37
0.22
Return on invested capital %
50.18
1.3
28.3
200.62
-20.05
49.65
Gross margin %
52.91
56.12
59.89
61.85
63.38
218.99
Operating margin %
21.71
1.77
12.42
52.58
4.25
45.11
EBITDA margin %
-45.63
-6.96
-7.7
-47.08
-5.07
-51.21
Net margin %
18.38
2.8
9.51
49.6
47.02
112.51
Liquidity ratios
Quick ratio
3.56
4.45
4.65
3.76
3.85
17.98
Current ratio
4.81
5.66
6.07
5.26
4.88
22.1
Inventory turnover
1.8
1.58
1.65
1.48
1.25
2.39
Asset turnover
0.37
0.41
0.45
0.54
0.51
0.57
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.92
0.57
0.3
0.12
0.37
0.56
EBIT per share
-5.15
-1.69
-1.83
-6.32
-0.8
-1.42
EBITDA per share
-4.19
-0.7
-0.83
-5.35
-0.41
-0.99
Total debt per share
—
—
—
—
—
—
Cash per share
6.91
6.45
8.31
7.43
5.38
21.53
Net current asset value per share
12.47
11.52
11.64
11.14
7.72
28.78
Tangible book value per share
12.15
13.46
13.98
13.65
9.81
38.52
Working capital per share
9.88
9.48
9.73
9.02
6.14
23.51
Book value per share
19.15
19.62
19.61
14.48
10.46
41.19
Haberler
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika 4Ç 2025 sunumu: ticari kanal büyümesi OEM düşüşünü telafi etti
Anika Q4 2025 slides: commercial surge offsets OEM decline
Anika kazancı $0,45 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek
Anika earnings beat by $0.45, revenue topped estimates
Lumicell appoints Cheryl Blanchard to board of directors
Anika Therapeutics, Stephen Griffin’i yeni CEO olarak atadı
Anika Therapeutics names Stephen Griffin as new CEO
Anika 2025 3. Çeyrek: Ticari büyüme OEM düşüşünü dengeliyor
Anika Q3 2025 slides: Commercial growth offsets OEM decline
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika earnings beat by $0.22, revenue was in line with estimates